BRAF in melanoma: current strategies and future directions.
Publication
, Journal Article
Salama, AKS; Flaherty, KT
Published in: Clin Cancer Res
August 15, 2013
Selective BRAF inhibitors have now been established as a standard of care option for patients diagnosed with metastatic melanoma whose tumors carry a BRAF mutation. Their successful development represents a milestone in the treatment of this disease, and has the potential to impact therapy for other malignancies as well. The use of these agents, however, has introduced a number of critical questions about the optimal use and selection of patients for BRAF inhibitor therapy. This review discusses the current status of BRAF inhibitor clinical development, the clinicopathologic features of BRAF-mutated melanoma, as well as strategies for overcoming resistance.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
August 15, 2013
Volume
19
Issue
16
Start / End Page
4326 / 4334
Location
United States
Related Subject Headings
- Signal Transduction
- Proto-Oncogene Proteins B-raf
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Mutation
- Molecular Targeted Therapy
- Melanoma
- Humans
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Salama, A. K. S., & Flaherty, K. T. (2013). BRAF in melanoma: current strategies and future directions. Clin Cancer Res, 19(16), 4326–4334. https://doi.org/10.1158/1078-0432.CCR-13-0779
Salama, April K. S., and Keith T. Flaherty. “BRAF in melanoma: current strategies and future directions.” Clin Cancer Res 19, no. 16 (August 15, 2013): 4326–34. https://doi.org/10.1158/1078-0432.CCR-13-0779.
Salama AKS, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013 Aug 15;19(16):4326–34.
Salama, April K. S., and Keith T. Flaherty. “BRAF in melanoma: current strategies and future directions.” Clin Cancer Res, vol. 19, no. 16, Aug. 2013, pp. 4326–34. Pubmed, doi:10.1158/1078-0432.CCR-13-0779.
Salama AKS, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013 Aug 15;19(16):4326–4334.
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
August 15, 2013
Volume
19
Issue
16
Start / End Page
4326 / 4334
Location
United States
Related Subject Headings
- Signal Transduction
- Proto-Oncogene Proteins B-raf
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Mutation
- Molecular Targeted Therapy
- Melanoma
- Humans
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis